Celularity Inc.
GXGX
NASDAQ Capital Market10.20
USD
+2.18
- -
Celularity Inc.
GXGX
(NASDAQ Capital Market)
Recent
price
10.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Celularity Inc. (Nasdaq: CELU), a clinical-stage biotechnology company headquartered in Florham Park, New Jersey and founded in 2017, develops and commercializes off-the-shelf allogeneic cell therapies and advanced biomaterials derived from the postpartum human placenta; its core offerings include unmodified and genetically modified natural killer (NK) cells, chimeric antigen receptor T-cells (CAR-T cells), mesenchymal-like adherent stromal cells (MLASCs or ASCs) targeting cancer, infectious diseases, immune disorders, and degenerative conditions, alongside cryopreserved placental-derived cell therapies and biomaterial products such as wound care solutions like Natalin, Acelagraft, and the recently acquired Rebound product line for regenerative applications. The company operates a fully integrated 150,000-square-foot GMP-capable manufacturing facility in New Jersey supporting clinical-scale production across cell therapy, degenerative disease, and biobanking segments, with primary revenue from biomaterial sales and biobanking services directed at healthcare providers, hospitals, and patients in the U.S. market. Recent developments include a strategic partnership with DefEYE Inc. featuring an exclusive sublicense and contract manufacturing for ophthalmic regenerative therapies following a $12 million seed investment; a collaboration with Fountain Life to deliver stem cell therapies under new Florida law; completion of a major balance sheet restructuring retiring $41.6 million in senior secured debt; acquisition of the Rebound biomaterial product from Sequence LifeScience expanding its commercial wound care portfolio; peer-reviewed Phase 2 trial publication confirming efficacy of PDA-002 cells for diabetic foot ulcers; FDA Tissue Reference Group recommendations for Natalin and Acelagraft; and full-year 2024 net revenues of $54.2 million reflecting 138% growth driven by over sevenfold Q3 product sales increase.
Why GX Acquisition Stock Soared Today
GXGX Merger: The SPAC News That Has GXGX Stock Soaring
GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal
GX Acquisition Corp. Announces Additional Contributions to Trust Account
7 Upcoming SPAC Mergers to Avoid
Global Nutrigenomics Market- Featuring BASF SE, Cell-Logic, Danone, DSM, and Genova Diagnostics Inc. Among Others | Technavio